T Cells, Graft-versus-Host Disease and Graft-versus-Leukemia: Innovative Approaches for Blood and Marrow Transplantation

Acta Haematologica

Volumn 95, Issue 3-4, 1996, Pages 157-163

  Champlin, Richard ^a   Giralt, Sergio ^a   Gajewski, James ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bone marrow transplantation; Graft versus host disease; Graft versus leukemia

Indexed keywords

BUSULFAN; IMMUNOSUPPRESSIVE AGENT; THIOTEPA;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; CANCER RECURRENCE; CELL TRANSPLANTATION; CONFERENCE PAPER; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC CELL; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA; PRIORITY JOURNAL; T LYMPHOCYTE;

BONE MARROW TRANSPLANTATION; GRAFT REJECTION; GRAFT VS HOST DISEASE; HUMANS; LEUKEMIA; LYMPHOCYTE DEPLETION; LYMPHOCYTE TRANSFUSION; LYMPHOCYTES; RECURRENCE; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 0029929379     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000203871     Document Type: Article

References (67)

1. Antin JH. Ferrara JLM: Cytokine dysregula-tion and acute graft-versus-host disease. Blood 1992;80:2964-2968.
2. Ferrara JLM. Deeg HJ: Mechanisms of disease: Graft-versus-host disease. N Engl J Med 1991; 324:667-674.
3. Korngold R, Sprent J: T cell subsets and graft-versus-host disease. Transplantation 1987;44: 335-339.
4. Ferrara JLM, Guillen FJ, van Dijken PJ, Marion A, Murphy GF, Burakoff SJ: Evidence that large granular lymphocytes of donor origin mediate acute graft-versus-host disease. Transplantation 1989:47:50-54.
5. Ferrara JLM: Advances in GVHD: Novel lymphocyte subsets and cytokine dysregulation. Bone Marrow Transplant 1992;10(suppl 1):10-12.
6. Ferrara JLM: Cytokine dysregulation as a mechanism of graft versus host disease. Curr Opion Immunol 1993;5:794-799.
7. Champlin RE: T-cell depletion for allogeneic bone marrow transplantation: Impact on graft-versus-host disease, engraftment, and graft-vcr-sus-lcukemia. J Hematother 1993;2:27-42.
8. Keever CA, Small TN, Flomenberg N, Heller G, Peklc K, Black P, Pecora A, Gillio A, Ker-nan NA, O’Reilly RJ: Immune rcconstitution following bone marrow transplantation: Comparison of recipients of T-cell depleted marrow with recipients of conventional marrow grafts. Blood 1989;73:1340-1350.
9. Johnson BD, Truitt RL: A decrease in graft-vs.-host disease without loss of graft-vs.-leukemia reactivity after MHC-matched bone marrow transplantation by selective depletion of donor NK cells in vivo. Transplantation 1992;54: 104-112.
10. Hale G, Waldmann H: Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies: Results of matched sibling transplants for malignant diseases. Bone Marrow Transplant 1994;13:597-611.
11. Berenson RJ, Bensinger WI, Hill RS, Andrews RG, Garcia-Lopez J, Kalamasz DF, Still BJ, Spitzer G, Buckner CD. Bernstein ID, Thomas ED: Engraftment after infusion of CD34+ marrow cells in patients with breast cancer or neuroblastoma. Blood 1991;77:1717-1722.
12. Cottler-Fox M, Cipolone K, Yu M, Berenson R, O’Shaughnessy J. Dunbar C: Positive selection of CD34+ hematopoietic cells using an immunoaffinity column results in T cell-deple-tion equivalent to elutriation. Exp Hematol 1995;23:320-322.
13. Mitsuyasu R, Champlin RE, Gale RP, Ho WG, Lanarsky C, Winston D. Selch M, Elashoff R, Giorgi JV, Wells J, Terasaki P, Billing R, Feig S: Depletion of T-lymphocytes from donor bone marrow' for the prevention of graft-ver-sus-host disease following bone marrow transplantation. Ann Intern Med 1986;105:20-26.
14. Reisner Y, Bcn-Bassat B, Douer D, Kaploon A, Schwartz E, Ramot B: Demonstration of clon-able allorcactive host T cells in a primate model for bone marrow transplantation. Proc Natl AcadSci USA 1986;83:4012-4015.
15. Butturini A, Seeger RC, Gale RP: Recipient immune-competent T lymphocytes can surv ive intensive conditioning for bone marrow' transplantation. Blood 1986:68:954-956.
16. Martin PJ, Hansen JA, Torok-Storb B, Dur-nam D, Przepiorka D, O’Quigley J, Sanders J, Sullivan KM, Witherspoon H, Deeg J, Appel-baum FR, Stewart P. Weiden P. Doney K, Buckner CD, Clift R. Storb R, Thomas ED: Graft failure in patients receiving T cell-de-pleted HLA-identical allogeneic marrow transplants. Bone Marrow Transplant 1989;3:445.
17. Kernan NA, Bordignon C, Heller G, Cunningham I, Castro-Malaspina H, Shank B, Flomenberg N, Burns J, Yang SY, Black P, Collins NH, O’Reilly RJ: Graft failure after T-cell-dcplctcd human leukocyte antigen identical marrow' transplants for leukemia. I: Analysis of risk factors and results of secondary' transplants. Blood 1989;74:2227-2236.
18. Vallera DA. Blazar BR: T cell depletion for graft-versus-host disease prophylaxis: A perspective on engraftment in mice and humans. Transplantation 1989;47:751-760.
19. Marmont AM. Horowitz MM, Gale RP, Sobo-cinski K. Ash RC, van Bekkum DW, Champlin RE, Dickc KA, Goldman JM. Good RA, Her-zig RH, Hong R, Masaoka T, Rimm AA, Ringden O, Speck B, Weiner RS, Bortin MM: T-cell depletion of HLA-identical transplants in leukemia. Blood 1991;78:2120-2130.
20. Kernan NA, Flomenberg N, Dupont B, O’Reilly RJ: Graft rejection in recipients of T-cell-deplcted HLA-nonidentical marrow transplants for leukemia. Transplantation 1997;43: 842.
21. Bordignon C, Keever CA, Small TN. Flomenberg N, Dupont B, O’Reilly RJ, Kernan NA: Graft failure after T-cell-depleted human leukocyte antigen identical marrow transplants for leukemia. II. In vitro analyses of host effector mechanism. Blood 1989;74:2237-2243.
22. Mackinnon S. Barnett L, Bourhis JH, Black P, Heller G, O'Reilly RJ: Myeloid and lymphoid chimerism after T-cell-depleted bone marrow transplantation: Evaluation of conditioning regimens using the polymerase chain reaction to amplify human minisatcllitc regions of genomic DNA. Blood 1992;80:3235-3241.
23. Lapidot T, Terenzi A, Singer TS, Salomon O, Reisner Y: Enhancement by dimethyl myleran of donor type chimerism in murine recipients of bone marrow allografts. Blood 1989;73: 2025-2032.
24. Lapidot T, Singer TS, Salomon O. Terenzi A, Schwartz E, Reisner Y: Booster irradiation to the spleen following total body irradiation: A new immunosuppressive approach for allogeneic bone marrow transplantation. J Immunol 1988;141:2619-2624.
25. Terenzi A, Lubin I, Lapidot T, Salomon O, Faktorowich Y. Rabi I, Martelli MF, Reisner Y: Enhancement of T cell-depleted bone marrow allografts in mice by thiotepa. Transplantation 1990;50:717-720.
26. Uharek L, Gassmann W, Glass B, Steinmann J, Loeffler H, Mueller-Ruchholtz W: Influence of cell dose and graft-versus-host reactivity on rejection rates after allogeneic bone marrow transplantation. Blood 1992;79:1612-1621.
27. Martin PJ: Donor CD8 cells prevent allogeneic marrow graft rejection in mice: Potential implications for marrow transplantation in humans. J Exp Med 1993;178:703-712.
28. Kaufman C, Colson YL, Wren SM, Watkins S, Simmons RL, Ildstad ST: Characterization of novel cell that facilitates engraftment of purified stem cells in an allogeneic MHC-disparate environment. Blood 1993;82(suppl l):456a.
29. Champlin R: Graft-versus-leukemia without graft-versus-host disease: An elusive goal of bone marrow transplantation. Semin Hematol 1992;29(suppl 2):46-52.
30. Sullivan KM, Storb R, Buckner CD, Fefer A, Fisher L. Weiden PL, Witherspoon RP, Appel-baum FR. Banaji M. Hansen J, Martin P, Sanders JE, Singer J, Thomas ED: Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N Engl J Med 1989;320:828-834.
31. Faber LM, Van Luxemburg-Heijs SAP, Wil-lemzc R, Falkenburg JHF: Generation of leukemia-reactive cytotoxic T lymphocyte clones from the HLA-identical bone marrow donor of a patient with leukemia. J Exp Med 1992,176: 1283-1289.
32. Sosman JA, Oettel KR, Hank JA, Fisch P, Son-del PM: Specific recognition of human leukemic cells by allogeneic T cell lines. Transplantation 1989;48:486-495.
33. Kolb HJ, Mittermiiller J, Clemm C, Holler E, Lcdderose G, Brehm G, Heim M, Wilmanns W: Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990;76: 2462-2465.
34. Drobyski WR, Keever CA, Roth MS, Koethe S, Hanson G. McFadden P, Gottschall JL, Ash RC, Van Tuinen P, Horowitz MM, Flomenberg N: Salvage immunotherapy using donor leukccyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow' transplantation: Efficacy and toxicity of a defined T-cell dose. Blood 1993;82: 2310-2318.
35. Hertenstein B, Wiesneth M, Novotny J, Bunjes D, Stefanic M. Heinze B, Hiibner G, Heimpel H, Arnold R: Interferon-a and donor buffy coat transfusions for treatment of relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation. Transplantation 1993;56: 1114-1118.
36. Antin JH: Graft-versus-leukemia: No longer an epiphenomenon. Blood 1993;82:2273-2277.
37. Kernan NA, Bartsch G, Ash RC, Beatty PG, Champlin R, Filipovich A, Gajewski J, Hansen JA, Henslee-Downey J, McCullough J, McGlave P, Perkins HA, Phillips GL, Sanders J, Stroncek D, Thomas ED, Blume KG: Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 1993;328:593-602.
38. Ash RC, Casper JT, Chitambar CR. Hansen R, Bunin N, Truitt RL. Lawton C, Murray K, Hunter J, Baxter-Lowe LA, Gottschall JL, Oldham K, Anderson T, Camitta B, Menitove J: Successful allogeneic transplantation of T-cell-depleted bone marrow from closely HLA-matched unrelated donors. N Engl J Med 1990; 322:485-494.
39. Bozdech MJ, Sondel PM, Trigg ME: Transplantation of HLA haploidentical T cell depleted marrow for leukemia: Addition of cytosine arabinoside to the transplant conditioning prevents graft rejection. Exp Hematol 1985; 13; 1201-1210.
40. O’Reilly RJ, Brochstcin J, Collins N, Kecvcr C, Kapoor N, Kirkpatrick D, Kernan N, Dupont B, Burns J, Rcisncr Y: Evaluation of HLA-haplotypc disparate parental marrow grafts depleted of T lymphocytes by differential agglutination with a soybean Icctin and E-rosette depletion for the treatment of severe combined immunodeficiency. Vox Sang 1986;51:81-86.
41. Reisner Y, Kapoor N. Kirkpatrick D. Pollack MS. Cunningham-Rundlcs S. Dupont B. Hodes MZ, Good RA, O’Reilly BJ: Transplantation for severe combined immunodeficiency with HLA-A.B.D. Dr incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells. Blood 1983:61: 341-348.
42. McGlave P, Bartsch G, Anasctti C, Ash R, Gajewski J, Kernan NA: Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: Initial experience of the National Marrow Donor Program. Blood 1993: 81:543-550.
43. Uharek L, Glass B, Gassmann W, Eckstein V, Stcinmann J, Loeffler H, Mueller-Ruchholtz W: Engraftment of allogeneic bone marrow cells: Experimental investigations on the role of cell dose, graft-vcrsus-host reactive T cells and pretransplant immunosuppression. Transplant Proc 1992;24:3023-3025.
44. Przcpiorka D, Huh YO, Khouri I, Reading C, Hester J, Marshall M, Champlin RE: Graft failure and graft-vcrsus-host disease after subtotal T-cell depleted marrow transplantation: Correlations with marrow hematopoietic and lymphoid subsets. Proc Clin Biol Res 1994,389: 557.
45. Koehler M, Hurwitz CA, Krance RA, Coustan-Smith E, Williams LL, Santana V, Ribciro RC, Brenner MK, Heslop HE: XomaZvme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors. Bone Marrow Transplant 1994; 13:571 — 575.
46. Bensinger WI, Weaver CH, Appelbaum FR, Rowley S, Dcmircr T, Sanders J, Storb R, Buckner CD: Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1995;85:1655-1658
47. Schmitz N, Drcger P, Suttorp M, Rohwedder EB, Haferlach T, Lofflcr H, Hunter A, Russell NH: Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 1995;85:1666-1672.
48. Korbling M, Przcpiorka D, Huh YO, Engel H, Van Besien K, Giralt S, Andersson B, Klcinc HD, Seong D, Deisscroth AB, Andreeff M, Champlin R: Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: Potential advantage of blood over marrow allografts. Blood 1995;85:1659-1665.
49. Avcrsa F, Tabilio A, Terenzi A, Velardi A, Fal-zctti F, Giannoni C, Iacucci R, Zei T, Martclli MP, Gambclunghc C, Rossetti M, Caputo P, Latini P, Aristci C, Raymondi C, Rcisncr Y, Martelli MF: Successful engraftment of T-ccll-dcpletcd haploidcntical ‘three-loci' incompatible transplants in leukemia patients by addition of recombinant human granulocyte colo-ny-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 1994;84:3948-3955.
50. Champlin R, Ho W, Gajewski J, Feig S, Burni-son M, Holley G, Greenberg P, Lee K, Schmid I, Giorgi J, Yam P, Pctz L, Winston D, Warner N, Reichert T: Selective depletion of CD8+ T lymphocytes for prevention of graft-versus-host disease after allogeneic bone marrow transplantation. Blood 1990;76:418-423.
51. Sprent J, Schaefer M, Lo D, Korngold R: Properties of purified T cell subsets. II. In vivo responses to class I vs. class II H-2 differences. J Exp Med 1986:163:998.
52. Korngold R: Pathophysiology of graft-versus-host disease directed to minor histocompatibility antigens. Bone Marrow Transplant 1991; 7(suppl 1);38—41.
53. Nimer SD, Giorgi J, Gajewski JL, Ku N, Schiller GJ, Lee K, Territo M, Ho W, Feig S, Selch M, Isacescu V, Reichert TA. Champlin RE: Selective depletion of CD8+ cells for prevention of graft-vcrsus-host disease after bone marrow transplantation: A randomized controlled trial. Transplantation 1994;57:82-87.
54. Champlin RE, Jansen J, Ho W, Gajewski J, Nimer S. Lee K, Territo M, Winston D, Tricot G, Reichert T: Retention of graft-versus-leuke-mia using selective depletion of CD8 positive T lymphocytes for prevention of graft versus host disease following bone marrow transplantation for chronic myelogenous leukemia. Transplant Proc 1991;23:1695-1696.
55. Jansen J, Hanks S, Akard L, Martin M, Thompson J. Chang Q, Ash R. Garrett P, Figg F, English D: Selective T cell depletion with CD8-conjugatcd magnetic beads in the prevention of graft-versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant 1995;15:271-278.
56. Schmidt-Wolf IGH, Dejbakhsh-Joncs S, Ginz-ton N, Greenberg P, Strober S: T-cell subsets and suppressor cells in human bone marrow. Blood 1992;80:3242-3250.
57. Soiffer RJ, Murray C, Gonin R, Ritz J: Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation. Blood 1994,84:964-971.
58. Kolb HJ, Mittermiiller J, Gunther W, Bartram C, Thalmaier K, Schumm M, Holler E. Lede-rosc G: Adoptive immunotherapy in human and canine chimeras. Bone Marrow Transplant 1993; 12(suppl 3):S61-S64.
59. Papadopoulos EB. Ladanyi M, Emanuel D, Mackinnon S, Boulad F. Carabasi MH. Castro-Malaspina H, Childs BH, Gillio AP, Small TN, Young JW. Kernan NA, O'Reilly RJ: Infusions of donor leukocytcs to treat Epstein-Barr virus-associated lvmphoproliferativc disorders after allogeneic bone marrow transplantation. N Engl J Med 1994;330:1185-1191.
60. Giralt SA, Champlin RE: Leukemia relapse after allogeneic bone marrow transplantation: A review. Blood 1994;84:3603-3612.
61. Van Rhce F, Lin F, Cullis JO, Spencer A, Cross NCP. Chase A, Garicochea B, Bungey J, Barrett J. Goldman JM: Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: The case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 1994;83:3377-3383.
62. Johnson BD, Truitt RL: Delayed infusion of immunocompetent donor cclls after bone marrow transplantation breaks graft-host tolerance and allows for persistent antileukemic reactivity without severe graft-vcrsus-host disease. Blood 1995;85:3302-3312.
63. Naparstek E, Or R, Nagler A, Cividalti G. Engelhard D, Aker M, Gimon Z, Manny N, Sacks T, Tochner Z, Weiss L, Samuel S, Braut-bar C, Hale G, Waldmann H, Steinberg SM, Slavin S: T-ccll-dcpleted allogeneic bone marrow' transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor’s peripheral blood lymphocytes for prevention of relapse. Br J Haematol 1995:89:506-515.
64. Mackinnon S. Papadopoulos EB, Carabasi MH, Reich L. Collins NH, Boulad F, Castro-Malaspina H. Childs B, Gillio A, Kernan NA. Small T. Young J. O’Reilly RJ: Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation. Separation of graft-versus-lcukemia responses from graft-versus-host disease. Blood 1995;86: 1261-1268.
65. Giralt S, Hester J, Huh Y, Hirsch-Ginsberg C, Rondon G, Guo J, Lee M, Gajewski J, Talpaz M, Kantarjian H, Fischer H, Deisseroth A, Champlin R: CD8+ depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: Graft vs leukemia without graft vs. host disease. Blood 1994:85: 4337-4343.
66. Tiberghien P, Reynolds CW, Keller J, Spence S, Deschaseaux M, Certoux JM, Contassot E, Murphy WJ, Lyons R, Chiang Y, Hcrve P, Longo DL, Ruscctti FW: Ganciclovir treatment of herpes simplex thymidine kinase-transduced primary T lymphocytes: An approach for specific in vivo donor T-cell depletion after bone marrow transplantation. Blood 1994:84:1333-1341.
67. Bonir, I C, Verzeletti S, Servida P, Rossini S, Traversari C, Ferrari G, Nobili N, Mavilio F, Bordigtion C: Transfer of the HSV-TK gene into donor peripheral blood lymphocytes for in vivo immunomodulation of donor anti-tumor immunity after allo-BMT. Blood 1994:84: 110a.